Nike Sale|Nike Factory Outlet Store nike sale,nike factory outlet store,nike outlet online,nike shoes for boys 3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticals Abbott Bringing More Interest to Galectin3 We saw fresh news regarding Galectin3 last week from Abbott Labs (ABT), which continued its excellence in the diagnostic products market with the CE marking of the Architect Galectin3 assay in Europe (link). Note that the CE Marking is similar to an FDA approval, and clears the product for market launch. This is exciting, as Galectin3 is a biomarker that is strongly prognostic for heart failure, which allows healthcare providers to identify those patients who are at higher risk for rehospitalization or death. Also exciting is the potential for Galectin3 to become a more prominent biomarker of cardiovascular risk in clinical trials, which could generate significant sales revenue for Abbott due to the sheer size of cardio risk trials. Two notable trials include: 1.) GlaxoSmithKline's (GSK) STABILITY trial for LpPLA2 inhibitor darapladib, which has an estimated enrollment of 15,828 2.) Amarin Corp's (AMRN) REDUCEIT trial for Eicosapentaenoic acid capsule Vascepa, which has an estimated enrollment of 8,000 With the introduction of Architect, Abbott has already introduced a very useful tool into the market for cardiovascular risk diagnostics, although (as mentioned below) Galectin3 may see additional potential as a biomarker in other diseases and indications. For instance, galectins may cause cells to migrate to new areas, or even multiply. "Galectins" refer to the 15 known lectins that bind specifically to and play a major role in the mediation of cellcell interactions adhesion. Also very interesting is their importance in the regulation of blood vessel growth, immune regulation, and inflammation. Galectins connect to with something known as a carbohydrate recognition domain (CRD), which is a section on these proteins that recognizes and interacts with the target, and "triggers" the effect that the Galectin was supposed to have. Galectin3 in particular is the oddball of the group due to its structure. The protein has a carbohydrate recognition domain and an Amino Acid tail, which allows it to form oligomers or "bundles" of Galectin3. Overexpression of Galectin3, which can form those "bundles," has been linked to cancer and organ failure in nonclinical studies. The Curious Case of GCS 100 As of now, the only drug that inhibits Galectin3 is GCS 100, a firstinclass Galectin3 agonist that was born at the Barbara Ann Karmanos Institute and originally developed by Prospect Therapeutics. Prospect collapsed in the financial maelstrom of 2008/2009, which ultimately allowed La Jolla Pharmaceutical Company (LJPC) to acquire the rights to the compound. Ongoing research suggests that Galectin3's role in various other diseases may be significant, as Galectin3 overexpression has been shown to lead to fibrosis and scarring of tissue which leads to additional complications found in other indications, but La Jolla is limiting itself to the diseases/indications that have the strongest links to Galectin3 overexpression. These include Chronic Kidney Disease (CKD), Chronic Liver Disease (cirrhosis), and cancer immunotherapy but not cardiovascular risk (possibly for strategic reasons). Treatment of CKD has proven difficult, and the disease generally leads to poor outcomes and comorbidities which is why CKD seems to be a particularly great indication for a firstinclass Galectin3 inhibitor. The drug's safety profile should prevent the outcome of Abbott and Reata Pharmaceuticals' bardoxolone a Phase III CKD therapy that was abandoned in 2012 after patients died in the trial. For the CKD indication in particular, GCS 100 is in a Phase I/II trial which just started enrolling at the beginning of the year. This implies that we will see fresh data in Q3 2013. The Takeaway New studies suggest that Galectin3 is a lot more important than we thought, and it may rise to prominence as a biomarker for cardiovascular risk (and other indications) due to the commercial availability of Abbott's Architect assay. Abbott is a diversified company that has probably the best overall product line for diagnostic products, and may have a big winner with Architect due to the overall importance of Galectin3. After its failure with bardoxolone last year, Abbott may be looking for another way to develop a CKD treatment. La Jolla happens to have the only Galectin3 inhibitor in clinical development, which synergizes not only with Abbott's presumed desire to play the CKD treatment market but with newly launched Architect assay which should help boost the overall profile for Galectin3. Source: Abbott: Galectin3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticals Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. (More.) Cheap Nikes Outlet store Online.Outfits with cheap nike shoes. See all outfits that use fashion brand NIKE and see how our fashionistas combine NIKE in her own and personal style. Get inspirations from we.